CRRT: The Technical Questions Modality & Dose

> Ashita J. Tolwani, MD, MSc University of Alabama at Birmingham 2018

Case

A 24YOM with HTN and OSA presents with acute pancreatitis. Despite aggressive fluid resuscitation and antibiotics for sepsis, he develops oliguric AKI with hyperkalemia. He is intubated on FIO_2 80% and is requiring vasopressin and norepinephrine. He is febrile and weighs 100 kg. He is on antibiotics and IV bicarbonate infusion. His labs are as follows:

Na 138 meq/L, K 6.5 meq/L, Cl 109 meq/L, HCO_3 22 meq/L, BUN 22 mg/dL, Creatinine 3.1 mg/dL (274 µmol/L); ABG: 7.21/pCO₂ 40 mmHg/pO₂ 108 mmHg on 80% FIO₂; WBC 13,000, Hct 30%, Platelets 104,000; Lactic acid 1.8 mmol/L; INR 1.6; Total Bili 3.2 mg/dL; ALT 694 U/L; AST 640 U/L; and CPK 22,000 U/L. He is 9 liters positive over last 24 hours.



Which CRRT modality do you place him on?

- A. CVVH with pre-filter RF
- B. CVVH with post-filter RF
- C. CVVH with pre- and post-filter RF
- D. CVVHD
- E. CVVHDF with pre-filter RF
- F. CVVHDF with post-filter RF
- G. CVVHDF with pre- and post- filter RF
- H. Any of the above
- I. None of the above
- J. I don't know

CRRT Treatment Goals

- Volume control
- Metabolic control
- Solute clearance
- Safe anticoagulation with minimal clotting

CRRT for AKI The Technical Questions


What are the critical elements of the CRRT prescription?

CRRT modality


Dose

- Anticoagulation
- Solutions

Molecular Weights



CRRT Modalities



SCUF

- No solute clearance
- removal

CVVH

- Solute clearance: convection
- Used for fluid Operative fluid: RF •

CVVHD

- Solute clearance: diffusion
- Operative fluid: dialysate

CVVHDF

- Solute clearance: diffusion and convection
- Operative fluids: RF and dialysate

Solute Clearance with CRRT

CVVH

CVVHD

CVVHDF

Calculating Solute Clearance

- Generic Clearance =
 - Mass removal rate / Blood concentration
 - Effluent flow rate x Effluent concentration/Blood concentration
 - $K = Q_E \times C_E / C_B$

Calculating Solute Clearance

Effluent Rate (ml/hr) Definition


- CVVH: Total UF Rate (ml/hr) = Pre-Filter Replacement Fluid Rate (ml/hr) + Post-Filter Replacement Fluid Rate (ml/hr) + Fluid Removal Rate (ml/hr)
- CVVHD: Dialysate Rate (ml/hr) + Fluid Removal Rate (ml/hr)
- CVVHDF: Total UF Rate (ml/hr) + Dialysate Rate (ml/hr) = Pre-Filter Replacement Fluid Rate (ml/hr) + Post-Filter Replacement Fluid Rate (ml/hr) + Fluid Removal Rate (ml/hr) + Dialysate Rate (ml/hr)

Calculating Solute Clearance

- Using urea as solute
 - Q_E << Q_B (17-50 ml/min vs. 150-200 ml/min)
 - Equilibrium achieved (C_E = C_B)
- $C_E/C_B = \sigma$ = Sieving Coefficient
- Sieving coefficients for small MW molecules such as urea = 1
- $K = Q_E \times C_E / C_B = Q_E \times 1$ (for urea) = Q_E
- Dose for CRRT is expressed as the effluent rate in ml/hr (Q_E) divided by patient weight = ml/kg/hr

CVVH

- Post-filter (post-dilution) replacement
- Pre-filter (pre-dilution) replacement
- Can be split into pre and post dilution replacement fluid



- Q_{TotalUF} = Total Ultrafiltration Rate*
- Q_P = Plasma Flow Rate
- Filtration Fraction (FF) = Total Ultrafiltration Rate / (Plasma Flow Rate + Pre-Filter Replacement Fluid Rate)
- Filter clotting with FF > 20-25%
- FF = 1500 / [6000 x (1-0.30)] = 0.36

*Remember Total UF = Replacement Fluid Rate (Pre and Post) + Fluid Removal Rate

Pre-Dilution Replacement Fluid

- Decreases filtration fraction
- Diminishes solute clearance by diluting blood reaching dialyzer
- Dilution Factor:


 $Q_{P} + Q_{R}$

 Q_{P}

- Q_P = blood water flow rate at the blood pump = Q_B X (1-HCT)
- Pre-dilutional CVVH clearance

• $K = Q_E \times [Q_P / (Q_P + Q_R)]$

CVVH Pre-Dilution RF



Dilution factor = $Q_p = 6000 (1 - 0.3) / [(6000 (1-0.3)) + 1500 ml/hr] = 0.74$ $Q_p + Q_R$


K_{urea} = 1.5 L/hr x 0.74 = 1.1 L/hr = 18 mL/min or 16 mL/kg/hr

24% decrease compared to post-dilution

 $FF = Q_{TotalUF} / (Q_P + Q_{Pre-RF}) = 1500 / [(6000(1 - 0.3)) + 1500] = 0.26$



Solute removal via diffusion dialysis



Effluent Rate (Q_E) = Dialysate Rate + Fluid Removal Rate* *Fluid Removal Rate can also be called Net UF Rate


K = Effluent flow rate $(Q_E) \times C_E/C_B$

Example Solute Calculation

- $K = Q_E \times C_E / C_B$
- CVVHD parameters
 - Pt. Wt. 70 kg
 - Dialysate Rate = 1500 mL/hr
 - Fluid Removal (or Net UF) = 0 mL/hr
 - BUN blood conc. = 60 mg/dL
 - BUN dialysate conc. = 60 mg/dL
- What is urea clearance?
 - K =1500 mL/hr X 1 = 1500 mL/hr = 25 mL/min or 21 ml/kg/hr

CVVHDF

Diffusion dialysis + Convective hemofiltration



Effluent Rate (Q_F) = Dialysate Rate + Total UF Rate

 $Q_{TotalUF} = Q_{R} + Q_{Fluid Removal}$

K = Effluent flow rate (Q_E) x C_E/C_B

Example Solute Calculation


CVVHDF parameters

Pt Wt. 70 kg Blood Flow Rate = 100 mL/min; hct = 30% Pre-filter Replacement Fluid Rate = 1500 mL/hr Dialysate Rate = 1500 mL/hr; Fluid Removal Rate = 0 mL/hr

 K = Q_E x [Q_P / (Q_P + Q_R)] K = 3000 X [6000 (1-0.3)]/[6000 (1-0.3)+1500] = 2211 ml/hr = 37 ml/min or 32 mL/kg/hr

FF = Q_{TotalUF} / (Q_P + Q_{Pre-filter RF}) = 1500 / [(6000(1-0.30)) + 1500] = 0.26

Convection vs. Diffusion



- Clearance is proportional to effluent rate for small molecular weight particles
- Increasing effluent rate increases solute clearance
- CVVH clearance = CVVHD clearance for same effluent rates for small molecular weight particles
 Brunet et al. Am J Kidney Dis 1999;34:486-492

Which CRRT Modality?

- Depends on CRRT device
- Depends on need for convective vs. diffusive therapy
- Depends on technical aspects of delivering dose (pre- vs. post dilution RF, filtration fraction, anticoagulation, etc.)

CRRT Machines

NxStage



Prismaflex



CRRT Machines

<u>NxStage</u>

- Has 3 pumps
 - Blood
 - Effluent
 - Dialysate or replacement fluid (preor post- replacement fluid)
- Can be used for SCUF, CVVH and CVVHD modalities.
- Cannot perform CVVHDF

<u>Prismaflex</u>

- Has 5 pumps
 - Blood
 - Effluent
 - Dialysate
 - Pre blood
 - Pre and/or Post Replacement fluid
- Can be used for SCUF, CVVH, CVVHD and CVVHDF modalities

Replacement Fluid Consideration for Prismaflex







DEAERATION CHAMBER

Manages air in the return line, the deaeration chamber provides a unique conveyance path that works like a vortex to propel all air out of the blood. Post-filter replacement solution is added into the deaeration chamber on top of the blood. Using a minimum of 200 to 500 ml/hr of post filter replacement will prevent air/blood interface. This is recommended to minimize clotting and foaming into deaeration chamber.

Are convective therapies better than diffusive therapies?

| | Hemofiltration | | Hemodialysis | | Risk Ratio | | Risk Ratio | |
|---|--|------------|--|-------------------------|----------------|---|--------------------|--|
| Study or Subgroup | Events T | otal | Events | - | Weight | IV, Random, 95% CI | IV, Random, 95% CI | |
| 1.1.1 Similar Dose Fit | 1.1.1 Similar Dose Filtration vs Dialysis | | | | | | | |
| Daud 2006 [25] | 7 | 9 | 10 | 11 | 14.7% | 0.86 [0.58, 1.27] | | |
| Morgera 2004 [24] | 6 | 12 | 6 | 12 | 6.1% | 1.00 [0.45, 2.23] | | |
| OMAKI 2012 [30] | 22 | 39 | 20 | 38 | 14.3% | 1.07 [0.71, 1.61] | | |
| Subtotal (95% CI) | | 60 | | 61 | 35.1% | 0.96 [0.73, 1.25] | - | |
| Total events | 35 | | 36 | | 222 | | | |
| Heterogeneity: Tau ² = Test for overall effect: | | | r= 2 (P = U | l.(4); l*∶ | = 0% | | | |
| 1.1.2 Similar Dose Fil | tration vs Dialy | /sis-F | iltration | | | | | |
| Chang 2009 [27] | 26 | 47 | 26 | 49 | 15.7% | 1.04 [0.72, 1.51] | _ | |
| Subtotal (95% CI) | | 47 | | 49 | 15.7% | 1.04 [0.72, 1.51] | - | |
| Total events | 26 | | 26 | | | | | |
| Heterogeneity: Not ap | plicable | | | | | | | |
| Test for overall effect: | Z = 0.22 (P = 0) | .82) | | | | | | |
| 1.1.3 Similar Dose (In | tormittont) Dia | heie | Filtration | ve Diak | veie | | | |
| Pettila 2001 [23] | 12 | 21 | -1 110 000 | 17 | 4.8% | 2.43 [0.95, 6.18] | | |
| Ratanarat 2012 [29] | 10 | 27 | 18 | 33 | 9.6% | 0.68 [0.38, 1.22] | | |
| Subtotal (95% CI) | 10 | 48 | 10 | 50 | 14.4% | 1.22 [0.35, 4.22] | | |
| Total events | 22 | | 22 | | | | | |
| Heterogeneity: Tau ² = | and the second | 15, di | and the second sec |).02); I ² : | = 81% | | | |
| Test for overall effect: | Z = 0.31 (P = 0 | .76) | | | | | | |
| | | | | | | | | |
| 1.1.4 Filtration vs High | | | | | | | | |
| Davenport 1993 [21] | 7 | 8 | 9 | 11 | 15.2% | 1.07 [0.73, 1.57] | | |
| Saudan 2006 [26] Subtotal (95% CI) | 67 | 102 110 | 43 | 104 115 | 19.6% 34.8% | 1.59 [1.21, 2.08] 1.34 [0.91, 1.96] | | |
| Total events | 74 | 110 | 52 | 115 | 34.070 | 1.54 [0.51, 1.50] | | |
| Heterogeneity: Tau ² = 0.05; Chi ² = 2.76, df = 1 (P = 0.10); l ² = 64% | | | | | | | | |
| Test for overall effect: $Z = 1.47$ (P = 0.14) | | | | | | | | |
| | | , | | | | | | |
| Total (95% CI) | | 265 | | 275 | 100.0% | 1.10 [0.88, 1.38] | * | |
| Total events | 157 | | 136 | | | | | |
| Heterogeneity: Tau ² = 0.05; Chi ² = 13.96, df = 7 (P = 0.05); I ² = 50% | | | | | | | | |
| Test for overall effect: Z = 0.87 (P = 0.38) Eavours Hemofiltration Eavours Hemofiltration | | | | | | Favours Hemofiltration Favours Hemodialysis | | |
| Test for subgroup differences: Chi ² = 1.97, df = 3 (P = 0.58), l ² = 0% | | | | | | | | |

HF Compared to HD for AKI: Systematic Review and Meta-analysis 19 RCTs 16 used CRRT

Friedrich JO, Wald R, Bagshaw SM, Burns KE, Adhikari NK. Crit Care. 2012 Aug 6; 16(4):R146

Dose of Acute RRT

There are no well-established standard methods for assessing efficacy of RRT in AKI

- Assessment of Dose in AKI limited to:
 - Urea kinetics in for IHD
 - BUN levels
 - Effluent volume in CRRT

Is There an Optimal Dose of RRT?



- 2008 VA/NIH Acute Renal Failure Trial (ATN) Network
- Large US multicenter RCT
- Primary endpoint: Death from any cause at day 60
- Objective: To determine the optimal intensity of RRT in critically ill patients with AKI

- 2009 RENAL Replacement Therapy Study Investigators
- Large Australian and New Zealand multicenter RCT
- Primary endpoint: Death within 90 days after randomization
- Objective: To determine the optimal intensity of RRT in critically ill patients with AKI

Bellomo R, *et al.* New Engl J Med 2009;361:1627-1638 Palevsky PM, *et al.* New Engl J Med 2008; 359:7-20


ATN Trial

| Modality | Intensive management strategy | Less-intensive management strategy | |
|---|-------------------------------------|--|--|
| Hemodynamically stable patients: IHD* | 6x/week | 3x/week | |
| Hemodynamically unstable patients: CVVHDF | 35 mL/kg/hr | 20 mL/kg/hr | |
| Hemodynamically unstable patients: SLED* | 6x/week | 3x/week | |

*target Kt/V: 1.2-1.4/treatment

Palevsky PM, et al. New Engl J Med 2008; 359:7-20


RENAL Trial




Bellomo R, et al. New Engl J Med 2009;361:1627-168

| Mortality at day 60 (%) | 52.5 | NR | |
|--|------|------|--|
| Mortality at day 90 (%) | NR | 44.7 | |
| Survivors dependant on RRT at day 28 (%) | 45.2 | 13.3 | |
| Survivors dependant on RRT at day 60 (%) | 24.6 | NR | |
| Survivors dependant on RRT at day 90 (%) | NR | 5.6 | |





60-




Prescribed vs Actual Delivered Dose

| | Standard dose (20 mg/kg/h) | High dose (35 mg/kg/h) | Р |
|--|-------------------------------|---------------------------|---------|
| Prescribed clearance (K _P) | 17.62 ± 0.96 | 28.10 ± 1.44 | <0.0001 |
| Estimated clearance (K_{E}) | 15.79 ± 2.47 | 25.10 ± 3.16 | <0.0001 |
| Urea clearance (K _u) | 15.55 ± 3.07 | 23.31 ± 5.30 | <0.0001 |
| Creatinine clearance (K _c) | 15.67 ± 3.88 | 21.62 ± 5.5 | <0.0001 |

CVVHDF Clearance Comparisons



Delivered RRT Dose and Survival



Kellum JA and Ronco C Nature Reviews Nephrology; 2010

Dosing of RRT in AKI

Intermittent hemodialysis

No need to provide treatments more than 3x/week so long as a target Kt/V_{urea} of 1.2-1.4 per treatment is achieved

Continuous renal replacement therapy

An effluent flow of at least 20 mL/kg/hr is sufficient, so long as there is careful attention to ensuring that the target dose of therapy is actually delivered

Delivered dose is less than prescribed dose

Clearances should be measured in routine care and used to optimize dose

What about high volume hemofiltration (HVHF) for sepsis?

- HVHF for Septic AKI: Meta-analysis
- **Objective:**
 - To evaluate the effects of HVHF compared with SVHF for septic AKI
- Methods:
 - Publications between1966 and 2013
 - RCTs that compared HVHF (effluent rate >50 ml/kg/hr) vs.
 SVHF in the treatment of sepsis and septic shock

What about high volume hemofiltration (HVHF) for sepsis?

Primary outcome: 28-day mortality

Secondary outcomes:

- Recovery of kidney function
- Lengths of ICU and hospital stay
- Vasopressor dose reduction

HVHF for Septic AKI

| Study | Location | Setting | Jadad scale | Primary endpoint | Follow-up |
|-----------------------------|--|-----------------------|-------------|---|-----------|
| Boussekey 2008 | France | Single- center ICU | 3 | 75% decrease in vasopressor dose after 24 hrs | 28 days |
| Sanchez (2010) | Spain | Single- center ICU | 1 | All cause mortality at 28 days | |
| Zhang (2012) | China | Single- center ICU | 2 | All cause mortality at 28 days | 90 days |
| Joannes- Boyau (2013) | France, Belgium, the Netherlands | 18 ICUS | 3 | All cause mortality at 28 days | 90 days |

Clark E, et al. Crit Care 2014;27:42-49


HVHF for Septic AKI

Details of high-volume and standard-volume hemofiltration (CVVH) for included studies

| Study | Prescribed effluent rate (mL/kg/hr) HVHF | Prescribed effluent rate (mL/kg/hr) control HVHF | Delivered effluent rate (mL/kg/hr) HVHF | Delivered effluent rate (mL/kg/hr) control HVHF | Days in ICU prior to enrollment HVHF | Days in ICU prior to enrollment control HVHF | Duration of HF (days) HVHF | Duration of HF (days) control HVHF |
|-----------------------------|--|---|---|--|--|---|-------------------------------------|--|
| Boussekey 2008 | 65 | 35 | 62 | 32 | Not stated | Not stated | 7 | 6 |
| Sanchez (2010) | 55 | 35 | | | | | 5.7 | 6.4 |
| Zhang (2012) | 85 | 50 | 87.54 | 49.99 | 5.4 | 6.2 | 9.38 | 8.88 |
| Joannes- Boyau (2013) | 70 | 35 | 65.6 | 33.2 | 2.4 | 1.9 | 6 | 7 |


Clark E, et al. Crit Care 2014;27:42-49

HVHF for Septic AKI Results




Clark E, et al. Crit Care 2014;27:42-49

Early HVHF vs Standard Care for Post-Cardiac Surgery Shock: HEROICS Study



Combes A, et al. Am J Crit Care Med 2015;27:1179-1190

Results



- Early HVHF did not lower Day-30 mortality and did not impact other important patient-centered outcomes compared with delayed CVVHDF initiation for patients with persistent, severe AKI
- HVHF patients experienced faster correction of metabolic acidosis and tended to be more rapidly weaned off catecholamines but had more frequent hypophosphatemia, metabolic alkalosis, and thrombocytopenia

High-Dose vs. Conventional-Dose CVVHDF and Patient and Kidney Survival and Cytokine Removal in Sepsis-AKI: A RCT

- SETTING & PARTICIPANTS:
 - Septic patients with AKI receiving CVVHDF for AKI
- INTERVENTION:
 - Conventional (40mL/kg/h) and high (80mL/kg/h) doses of CVVHDF
- OUTCOMES:
 - Patient and kidney survival at 28 and 90 days, circulating cytokine levels
- RESULTS:
 - 212 patients randomized
 - No differences in 28-day mortality (HR, 1.02; 95% CI, 0.73-1.43; P=0.9) or 28-day kidney survival (HR, 0.96; 95% CI, 0.48-1.93; P=0.9) between groups
 - High-dose CVVHDF, but not the conventional dose, significantly reduced interleukin 6 (IL-6), IL-8, IL-1b, and IL-10 levels

HICORES Investigators. Am J Kidney Dis. 2016

Case

A 24YOM with HTN and OSA presents with acute pancreatitis. Despite aggressive fluid resuscitation and antibiotics for sepsis, he develops oliguric AKI with hyperkalemia. He is intubated on FIO₂ 80% and is requiring vasopressin and norepinephrine. He is febrile and weighs 100 kg. He is on antibiotics and IV bicarbonate infusion. His labs are as follows:

Na 138 meq/L, K 6.5 meq/L, Cl 109 meq/L, HCO₃ 22 meq/L, BUN 22 mg/dL, Creatinine 3.1 mg/dL; ABG: 7.21/pCO₂ 40 mmHg/pO₂ 108 mmHg on 80% FIO₂; WBC 13,000, Hct 30%, Platelets 104,000; Lactic acid 1.8 mmol/L; INR 1.6; Total Bili 3.2 mg/dL; ALT 694 U/L; AST 640 U/L; and CPK 22,000 U/L. He is 9 liters positive over last 24 hours.

Case

Which CRRT modality do you place him on?

- A. CVVH with pre-filter RF
- B. CVVH with post-filter RF
- C. CVVH with pre- and post-filter RF
- D. CVVHD
- E. CVVHDF with pre-filter RF
- F. CVVHDF with post-filter RF
- G. CVVHDF with pre- and post- filter RF
- H. Any of the above
- I. None of the above
- J. I don't know

Patient is placed on the following CRRT Rx:

CRRT Parameters:

- CVVH with NxStage
- BF: 100 ml/min
- Post-filter RF: 1500 ml/hr
- Fluid Removal: 200 ml/hr
- No anticoagulation

What are your thoughts on prescription?

- CRRT modality?
- Dose?
- Filtration fraction?
- Anticoagulation?

Dose?

V

- CVVH
- BF: 100 ml/min
- Post-filter RF: 1500 ml/hr
- Fluid Removal: 200 ml/hr
- Patient weight: 100 kg

Hct: 30%

Effluent Rate = 1500 ml/hr + 200 ml/hr = 1700 ml/hr
 Dose = 1700 / 100 kg = 17 ml/kg/hr

Post-filter Replacement Fluid Rate: 1500 mL/hr

 \mathbf{V}

 Q_R

Q_B 100 mL/min

Filtration Fraction?

- BF: 100 ml/min
- Post-filter RF: 1500 ml/hr
- Fluid Removal: 200 ml/hr
- Patient weight: 100 kg
- Hct: 30%

- $FF = Q_{UF} / (Q_P + Q_{Pre-filter RF})$
- Q_P = [Q_B x (1- Hct)]
- $FF = (Q_R + Q_{netUF}) / [Q_B (1 0.3)]$
- FF = (1500 + 200)/[(6000 x 0.7)] = 40%
- FF > 25-30%, clotting can occur

Patient is placed on following CRRT prescription:

CRRT Parameters:

- CVVH with Prismaflex
- BF: 200 ml/min
- Pre-filter RF: 2000 ml/hr
- Fluid Removal: 200 ml/hr
- Post-filter RF: 200 ml/hr
- Anticoagulation: ACD-A 2.2% 300 ml/hr delivered through PBP


What are your thoughts on prescription?

- CRRT modality?
- Dose (prescribed and delivered)?
- Filtration fraction?
- Anticoagulation?

Dose?

- Effluent Rate = 2000 ml/hr + 200 ml/hr + 200 ml/hr + 300 ml/hr = 2700 ml/hr
- Dose = 2700 / 100 kg = 27 ml/kg/hr
- Dilution factor = (12000 x 0.7)/ [(12000 x 0.7) + 2300] = 0.81
- Dose = 27 ml/kg/hr x 0.81 = 22 ml/kg/hr

- CVVH
- BF: 200 ml/min
- Pre-filter RF: 2000 ml/hr
- Post-filter RF: 200 ml/hr
- Fluid Removal: 200 ml/hr
- Patient weight: 100 kg
- AC: ACD-A 300 ml/hr
- Hct: 30%



Filtration Fraction?

• $FF = Q_{UF} / (Q_P + Q_{Pre-filter RF})$

- CVVH
- BF: 200 ml/min
- Pre-dilution: 2000 ml/hr
- Post-filter RF: 200 ml/hr
- Fluid Removal: 200 ml/hr
- Patient weight: 100 kg
- AC: ACD-A 300 ml/hr
- Hct: 30%
- $FF = (Q_{Pre-filter} + Q_{Post-filter} + Q_{NetUF} + Q_{PBP}) / [Q_B (1-0.3) + 2000 + 300]$
- FF = $(2000 + 200 + 200 + 300)/[(12000 \times 0.7) + 2300] = 25\%$
- FF > 25-30%, clotting can occur